Cargando…

Pirfenidone, an Anti-Fibrotic Drug, Suppresses the Growth of Human Prostate Cancer Cells by Inducing G(1) Cell Cycle Arrest

Pirfenidone (PFD) is an anti-fibrotic drug used to treat idiopathic pulmonary fibrosis by inducing G(1) cell cycle arrest in fibroblasts. We hypothesize that PFD can induce G(1) cell cycle arrest in different types of cells, including cancer cells. To investigate the effects of PFD treatment on the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishii, Kenichiro, Sasaki, Takeshi, Iguchi, Kazuhiro, Kato, Manabu, Kanda, Hideki, Hirokawa, Yoshifumi, Arima, Kiminobu, Watanabe, Masatoshi, Sugimura, Yoshiki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351920/ https://www.ncbi.nlm.nih.gov/pubmed/30621175 http://dx.doi.org/10.3390/jcm8010044

Ejemplares similares

Loss of Fibroblast-Dependent Androgen Receptor Activation in Prostate Cancer Cells is Involved in the Mechanism of Acquired Resistance to Castration
por: Ishii, Kenichiro, et al.
Publicado: (2019)

Successful Preservation of the Bladder in a Case of Inflammatory Myofibroblastic Tumor with the Diagnostic Efficacy of ALK/p80 Immunohistochemistry and FISH Analysis: Case Report and Review of the Literature
por: Kato, Manabu, et al.
Publicado: (2017)

Successfully Treated Lung and Renal Metastases from Primary Chondrosarcoma of the Scapula with Radiofrequency Ablation and Surgical Resection
por: Sekito, Sho, et al.
Publicado: (2019)

Role and New Insights of Pirfenidone in Fibrotic Diseases
por: Lopez-de la Mora, David Alejandro, et al.
Publicado: (2015)

Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts
por: Zhou, Chaoming, et al.
Publicado: (2016)

The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC
por: Marwitz, Sebastian, et al.
Publicado: (2020)

Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1
por: Jin, Jin, et al.
Publicado: (2019)

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts
por: Mediavilla-Varela, Melanie, et al.
Publicado: (2016)

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
por: Molina-Molina, M., et al.
Publicado: (2018)

Pirfenidone-induced Eosinophilic Pleurisy
por: Hase, Isano, et al.
Publicado: (2017)

Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation
por: Ballester, Beatriz, et al.
Publicado: (2020)

Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone
por: Ma, Hsiao-Yen, et al.
Publicado: (2023)

Role of Stromal Paracrine Signals in Proliferative Diseases of the Aging Human Prostate
por: Ishii, Kenichiro, et al.
Publicado: (2018)

Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone
por: Andersen, Stine, et al.
Publicado: (2019)

The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1
por: Xi, Yue, et al.
Publicado: (2021)

Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis
por: Bracco Gartner, Thomas C. L., et al.
Publicado: (2022)

A case of adenocarcinoma of the rete testis with durable response to cisplatin‐based chemotherapy
por: Owa, Shunsuke, et al.
Publicado: (2021)

A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
por: Shah, Parth V, et al.
Publicado: (2021)

Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro
por: Wei, Qilu, et al.
Publicado: (2021)

Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis
por: Fernández Pérez, Evans R., et al.
Publicado: (2021)

Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer
por: Sasaki, Takeshi, et al.
Publicado: (2021)

Correction to: Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro
por: Wei, Qilu, et al.
Publicado: (2021)

The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?
por: Ferrara, Francesco, et al.
Publicado: (2020)

Pirfenidone: is it tolerable?
por: Lara, Abigail, et al.
Publicado: (2016)

The in vitro anti-fibrotic effect of Pirfenidone on human pterygium fibroblasts is associated with down-regulation of autocrine TGF-β and MMP-1
por: Tao, Yijin, et al.
Publicado: (2020)

The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients
por: Sasaki, Takeshi, et al.
Publicado: (2018)

Inflammatory suppressive effect of prostate cancer cells with prolonged exposure to transforming growth factor β on macrophage-differentiated cells via downregulation of prostaglandin E(2)
por: HAYASHI, AKINOBU, et al.
Publicado: (2014)

Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients
por: Feng, Haoshen, et al.
Publicado: (2020)

Biphasic Effect of Pirfenidone on Angiogenesis
por: Gan, Donghao, et al.
Publicado: (2022)

Inhibition of Ureteral Stricture by Pirfenidone-Loaded Nanoparticle-Coated Ureteral Stents with Slow-Release Pirfenidone
por: Jiang, Zhaosheng, et al.
Publicado: (2022)

Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)

Role of pirfenidone in the management of pulmonary fibrosis
por: Meyer, Keith C, et al.
Publicado: (2017)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)

Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration
por: Ikeda, Satoshi, et al.
Publicado: (2022)

Anti-fibrotic effect of adipose-derived stem cells on fibrotic scars
por: Vanderstichele, Sophie, et al.
Publicado: (2022)

Clinical impact of high-attenuation and cystic areas on computed tomography in fibrotic idiopathic interstitial pneumonias
por: Tanizawa, Kiminobu, et al.
Publicado: (2015)

T Cells in Fibrosis and Fibrotic Diseases
por: Zhang, Mengjuan, et al.
Publicado: (2020)

Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2
por: Antar, Samar A., et al.
Publicado: (2022)

Anti-fibrotic potential of erythropoietin signaling on bone marrow derived fibrotic cell
por: Iwata, Yasunori, et al.
Publicado: (2021)

The multifaceted role of pirfenidone and its novel targets
por: Macías-Barragán, José, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_j7oadretcevbj6uooatj48hnm3